Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, the full-spectrum cannabis extract VER-01 was tested against placebo over 12 weeks for chronic low back pain, with follow-up extending to approximately one year. The trial design includes both a blinded treatment phase and an open-label extension, providing data on both short-term efficacy and longer-term safety and durability of effect. Results from this rigorously structured study contribute meaningful clinical evidence to the limited pharmacologic options currently available for chronic low back pain.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based therapeutics in chronic low back pain, a condition affecting over 500 million people globally with currently limited safe and effective pharmacologic options. The large sample size (n=820) and robust design including both blinded and open-label phases generate the quality of evidence needed to inform clinical decision-making and potential regulatory approval for an alternative pain management strategy. Given the opioid crisis and inadequacy of conventional treatments, demonstration of efficacy and safety for full-spectrum cannabis extract could significantly expand the therapeutic armamentarium for this high-burden condition.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial represents meaningful progress in evaluating cannabis-based medicine for chronic low back pain, a condition where conventional pharmacotherapy often falls short. However, several factors warrant careful interpretation: the study used a proprietary full-spectrum extract (VER-01) from a specific cannabis strain, limiting generalizability to other cannabis formulations or cultivars that patients might encounter in clinical practice, and the abstract does not specify the cannabinoid content or ratios, making it difficult to identify which compounds may drive efficacy. The 12-week double-blind phase provides solid evidence for short-term effects, though the open-label extension introduces bias that limits conclusions about long-term safety and tolerability. For clinicians considering cannabis medicine in CLBP, these results suggest potential benefit in selected patients, but the specific formulation tested may not be readily available, and individual patient factors such as concurrent medications, liver function, and psychiatric history remain critical variables in determining appropriateness and monitoring.
| |